There seems to be some confusion about the status of AOD and how...

There seems to be some confusion about the status of AOD and how it is reported in the press.


http://www.crimecommission.gov.au/publications/other-publications/organised-crime-drugs-sport/performance-image-enhancing-substances

"Growth Hormone Variants

AOD-9604 is a variant of growth hormone which has fat burning properties and may be used by athletes to increase power to weight ratios by better utilisation of fat stores.

AOD-9604 is about to enter phase three clinical trials.12 During phase two clinical trials it was also found to have an anabolic effect on cartilage tissue and may promote cartilage creation and repair and have a capacity to enhance muscle formation.13

AOD-9604 is not currently a WADA prohibited substance."

If AOD isn`t a prohibited substance and isn`t performance enhancing it could be taken legally under a clincal trial setting with I`m sure plenty of participants wanting to have a try.

I must say I had given up on ever seeing a return on AOD 9604, however I revisited this from a CZD announcement on 13/03/2012, there might be some prospect for arthritis sufferers without discounting weight loss as a side effect!!

Worth reading again, any arthritis application would give some life to the patent.

AOD9604 Shows Positive Results in Cartilage and Muscle Repair Models
Calzada Ltd’s (‘Calzada’) wholly owned subsidiary, Metabolic Pharmaceuticals Pty Ltd (‘Metabolic’), is pleased
to announce that it has received positive results from in-vitro tests conducted on its peptide compound,
AOD9604, at the Mt Sinai Hospital, Toronto, Canada under the direction of Professor Marc Grynpas and
Professor Rita Kandel. These studies were conducted in separate cartilage and muscle cell experiments using
animal cell lines and were designed to explore the further commercial potential of the AOD9604.
Key Research Findings
The research results provide evidence that AOD9604:
1. Has a positive (anabolic) effect on cartilage tissue formation. AOD9604 was found to enhance
cartilage tissue formation by increasing the proteoglycan (cellular matrix) and collagen content
of cartilage;
2. Enhances the differentiation of muscle progenitor cells (cells that create muscle cells) to
muscle cells.
No cell toxicity was caused by AOD9604 in any of the studies.
What These Results Mean
These results mean that AOD9604 might promote cartilage creation and repair and may have a capacity to
enhance muscle formation. This may be particularly useful in fields such as Osteoarthritis and diseases where
muscle mass loss is a dominant factor.
In commenting on the research findings Dr Kandel said “These results are exciting because they provide early
stage evidence that AOD9604 may help to repair damaged cartilage and muscle tissue.”
Potential Utility of AOD9604 in Cartilage and Muscle Applications
This encouraging efficacy data when combined with the highly favourable safety profile of AOD9604, proven in
toxicology studies and six human clinical trials, provides strong rationale for use of the peptide where cartilage
or muscle quality is compromised or in need of repair.
For example, AOD9604 may have potential for support in patients with Osteoarthritis and other diseases in
which cartilage and muscle degeneration feature as key pathologies, such as Costochondritis (inflammation of
cartilage in the ribs), Sarcopenia (age-related loss of muscle mass) and Cachexia (various muscle wasting
syndromes).
It might also be possible to use AOD9604 to promote recovery from trauma, burns and other situations where
muscle and cartilage damage occurs in otherwise healthy individuals such as in sports injuries.
AOD9604 could offer advantages as it can be given orally and has an outstanding safety record.

Potential Osteoarthritis Market
The potential uses outlined above target support in conditions, trauma and injuries with very large markets and
where there are limited or no adequate treatment options. For instance in the case of Osteoarthritis:
“GlobalData estimates that the global Osteoarthritis (OA) market was worth $4.4 billion in 2010 and forecasts it to grow at a compound annual
growth rate of 3.8% to reach $5.9 billion by 2018. The current treatment options for OA offer only symptomatic relief and are primarily dominated
by generics. There are no disease modifying osteoarthritis drugs (DMOAD) currently approved in the OA therapeutics market and the late stage
pipeline also lacks DMOADs ...... Owing to all the above factors the OA therapeutics market is expected to show slow growth till 2018.”
Source PRNewswire,